Prof. Dr Sven Francque (University of Antwerp, Belgium) kindly spoke with us about the additional analysis of the phase 2b NATIVE trial investigating lanifibranor in patients with NASH.
His presentation entitled ‘Lanifibranor therapy improves markers of lipid metabolism, insulin resistance, liver injury and fibrosis in patients with NASH and F2 and F3 fibrosis stages: a subgroup analysis of the phase 2b NATIVE study’ was given at EASL ILC 2021, 23-26 June.
- What is the rationale for the use of lanifibranor therapy in patients with NASH? (0:10)
- Could you briefly describe the aims, design and patient population of the NATIVE trial? (1:03)
- What were the effects of lanifibranor therapy on histological endpoints, and how did findings in the F2/F3 population compare with those of the overall patient population? (1:51)
- What effect did lanifibranor have on markers of liver injury, inflammation and fibrosis? (2:27)
- What was the safety and tolerability profile of lanifibranor? (3:27)
Disclosures: Prof. Dr Sven Francque has served as a speaker for AbbVie, Allergan, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Genentech, Genfit, Gilead, Intercept Pharmaceuticals, Inventiva, Novartis, NGM Bio, NovoNordisk and Roche. He has also acted as a consultant for AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Genentech, Genfit, Gilead, Intercept Pharmaceuticals, Inventiva, Novartis, NGM Bio, Novo Nordisk and Roche.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
Share this Video
Related Videos In Liver Disorders
Quentin Anstee: Highlights from the Digital NAFLD Summit 2021
touchENDOCRINOLOGY joins Professor Quentin Anstee (Newcastle University, UK) at the Digital NAFLD Summit 2021 to discuss his highlights from the conference and new, exciting developments in the field. Questions 1. Are you pleased with how the European Association for the Study of the Liver (EASL) NAFLD Summit 2021 went this year? (00:23-01:00) 2. What were […]
Quentin Anstee, Digital NAFLD Summit 2021: Exciting Advances and New Research into the Management of Non-alcoholic Fatty Liver Disease
touchENDOCRINOLOGY joins Professor Quentin Anstee (Newcastle University, UK) at the Digital NAFLD Summit 2021 to discuss his highlights from the conference and new, exciting developments in the field. Questions 1. Please summarise the prevalence of non-alcoholic fatty liver disease (NAFLD) and the clinical unmet needs in this area? (00:20-01:00) 2. What are the current most […]
Jean-François Dufour, UEG 2021: Treatment Pipeline for NASH
It was a pleasure to speak with Prof. Jean-François Dufour (University of Bern, Bern, Switzerland) about drug development in non-alcoholic steatohepatitis (NASH) and in particular the farnesoid X receptor (FXR) as a therapeutic target. His presentation entitled ‘Treatment of NASH: What is in the pipeline?’ was given at UEG week, 2-5 Oct 2021. Questions What […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!